RESUMEN
Specific neurotrophic factors mediate histological and/or functional improvement in animal models of traumatic brain injury (TBI). In previous work, several lines of evidence indicated that the mammalian neurotrophin NT-4/5 is neuroprotective for hippocampal CA3 pyramidal neurons after experimental TBI. We hypothesized that NT-4/5 neuroprotection is mediated by changes in the expression of specific sets of genes, and that NT-4/5-regulated genes are potential therapeutic targets for blocking delayed neuronal death after TBI. In this study, we performed transcription profiling analysis of CA3 neurons to identify genes regulated by lateral fluid percussion injury, or by treatment with the trkB ligands NT-4/5 or brain-derived neurotrophic factor (BDNF). The results indicate extensive overlap between genes upregulated by neurotrophins and genes upregulated by injury, suggesting that the mechanism behind neurotrophin neuroprotection may mimic the brain's endogenous protective response. A subset of genes selected for further study in vitro exhibited neuroprotection against glutamate excitotoxicity. The neuroprotective genes identified in this study were upregulated at 30 h post-injury, and are thus expected to act during a clinically useful time frame of hours to days after injury. Modulation of these factors and pathways by genetic manipulation or small molecules may confer hippocampal neuroprotection in vivo in preclinical models of TBI.
Asunto(s)
Lesiones Encefálicas/genética , Región CA3 Hipocampal/efectos de los fármacos , Región CA3 Hipocampal/lesiones , Regulación de la Expresión Génica/efectos de los fármacos , Factores de Crecimiento Nervioso/farmacología , Neuronas/efectos de los fármacos , Animales , Lesiones Encefálicas/patología , Región CA3 Hipocampal/metabolismo , Región CA3 Hipocampal/patología , Masculino , Microdisección , Neuronas/metabolismo , Neuronas/patología , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Regulación hacia Arriba/efectos de los fármacosRESUMEN
Neural progenitor cells (NPCs) have been investigated as potential vehicles for brain tumor therapy because they have been shown to migrate toward central nervous system gliomas and can be genetically engineered to deliver cytotoxic agents to tumors. The mechanisms that regulate migration of NPCs to tumors are not fully understood. By means of microarray analysis, polymerase chain reaction, enzyme-linked immunosorbent assay, and immunohistochemistry, we found that monocyte chemoattractant protein-1 (MCP-1/CCL-2) was expressed in experimental brain tumor cells in vivo and in vitro. CCR2, the receptor for MCP-1, was expressed on C17.2 NPCs. We used a modified Boyden chamber assay and found increased migration of NPCs in vitro in response to MCP-1. By means of an in vivo model for NPC migration, we found evidence of NPC migration toward areas of MCP-1 infusion in rat brains. An understanding of NPC migration mechanisms may be used to enhance delivery of cytotoxic agents to brain tumor cells.
Asunto(s)
Neoplasias Encefálicas/fisiopatología , Movimiento Celular/fisiología , Quimiocina CCL2/metabolismo , Glioma/fisiopatología , Neuronas/fisiología , Células Madre/fisiología , Animales , Encéfalo/patología , Encéfalo/fisiopatología , Neoplasias Encefálicas/patología , Línea Celular , Línea Celular Tumoral , Femenino , Glioma/patología , Trasplante de Neoplasias , Ratas , Ratas Endogámicas F344 , Receptores CCR2/metabolismo , Trasplante de Células MadreRESUMEN
PURPOSE: The ability of brain-derived neurotrophic factor (BDNF) to attenuate secondary damage and influence behavioral outcome after experimental traumatic brain injury (TBI) remains controversial. Because TBI can result in decreased expression of the trkB receptor, thereby preventing BDNF from exerting potential neuroprotective effects, the contribution of both BDNF and its receptor trkB to hippocampal neuronal loss and cognitive dysfunction were evaluated. METHODS: Full-length trkB was overexpressed in the left hippocampus of adult C57Bl/6 mice using recombinant adeno-associated virus serotype 2/5 (rAAV 2/5). EGFP (enhanced green fluorescent protein) expression was present at two weeks after AAV-EGFP injection and remained sustained up to four weeks after the injection. At 2 weeks following gene transduction, mice were subjected to parasagittal controlled cortical impact (CCI) brain injury, followed by either BDNF or PBS infusion into the hippocampus. RESULTS: No differences were observed in learning ability at two weeks post-injury or in motor function from 48 hours to two weeks among treatment groups. The number of surviving pyramidal neurons in the CA2-CA3 region of the hippocampus was also not different among treatment groups. CONCLUSIONS: These data suggest that neither overexpression of trkB, BNDF infusion or their combination affects neuronal survival or behavioral outcome following experimental TBI in mice.
Asunto(s)
Lesiones Encefálicas/complicaciones , Trastornos del Conocimiento , Hipocampo/patología , Neuronas/fisiología , Receptor trkB/fisiología , Transducción Genética/métodos , Análisis de Varianza , Animales , Lesiones Encefálicas/patología , Lesiones Encefálicas/terapia , Recuento de Células/métodos , Trastornos del Conocimiento/etiología , Trastornos del Conocimiento/patología , Trastornos del Conocimiento/terapia , Dependovirus/fisiología , Modelos Animales de Enfermedad , Proteínas Fluorescentes Verdes/biosíntesis , Masculino , Aprendizaje por Laberinto/fisiología , Ratones , Ratones Endogámicos C57BL , Actividad Motora/fisiología , Tiempo de Reacción , Receptor trkB/genética , Factores de TiempoRESUMEN
Most current methods of gene delivery for primary cultured hippocampal neurons are limited by toxicity, transient expression, the use of immature neurons and/or low efficiency. We performed a direct comparison of seven serotypes of adeno-associated virus (AAV) vectors for genetic manipulation of primary cultured neurons in vitro. Serotypes 1, 2, 7, 8 and 9 mediated highly efficient, nontoxic, stable long-term gene expression in cultured cortical and hippocampal neurons aged 0-4 weeks in vitro; serotypes 5 and 6 were associated with toxicity at high doses. AAV1 transduced over 90% of all cells with approximately 80% of the transduced cells being neurons. The method was readily adapted to a high-throughput format to demonstrate neurotrophin-mediated neuroprotection from glutamate toxicity in cultured neurons at 2 weeks in vitro. These vectors should prove highly useful for efficient overexpression or downregulation of genes in primary neuronal cultures at any developmental stage.
Asunto(s)
Dependovirus/clasificación , Proteínas Fluorescentes Verdes/metabolismo , Neuronas/metabolismo , Transducción Genética/métodos , Transfección/métodos , Transgenes/genética , Animales , Astrocitos/citología , Astrocitos/metabolismo , Astrocitos/virología , Técnicas de Cultivo de Célula , Células Cultivadas , Corteza Cerebral/citología , Dependovirus/genética , Regulación de la Expresión Génica , Vectores Genéticos , Proteínas Fluorescentes Verdes/genética , Hipocampo/citología , Neuronas/citología , Neuronas/virología , Ratas , Ratas Sprague-Dawley , SerotipificaciónRESUMEN
OBJECT: Central nervous system axons regenerate poorly after traumatic brain injury (TBI), partly due to inhibitors such as the protein Nogo-A present in myelin. The authors evaluated the efficacy of anti-Nogo-A monoclonal antibody (mAb) 7B12 administration on the neurobehavioral and cognitive outcome of rats following lateral fluid-percussion brain injury, characterized the penetration of the 7B12 or control antibodies into target brain regions, and evaluated the effects of Nogo-A inhibition on hemispheric tissue loss and sprouting of uninjured motor tracts in the cervical cord. To elucidate a potential molecular response to Nogo-A inhibition, we evaluated the effects of 7B12 on hippocampal GAP-43 expression. METHODS: Beginning 24 hours after lateral fluid-percussion brain injury or sham injury in rats, the mAb 7B12 or control antibody was infused intracerebroventricularly over 14 days, and behavior was assessed over 4 weeks. RESULTS: Immunoreactivity for 7B12 or immunoglobulin G was detected in widespread brain regions at 1 and 3 weeks postinjury. The brain-injured animals treated with 7B12 showed improvement in cognitive function (p < 0.05) at 4 weeks but no improvement in neurological motor function from 1 to 4 weeks postinjury compared with brain-injured, vehicle-treated controls. The enhanced cognitive function following inhibition of Nogo-A was correlated with an attenuated postinjury downregulation of hippocampal GAP-43 expression (p < 0.05). CONCLUSIONS: Increased GAP-43 expression may be a novel molecular mechanism of the enhanced cognitive recovery mediated by Nogo-A inhibition after TBI in rats.
Asunto(s)
Anticuerpos Monoclonales/farmacología , Lesiones Encefálicas/tratamiento farmacológico , Proteína GAP-43/metabolismo , Hipocampo/metabolismo , Proteínas de la Mielina/antagonistas & inhibidores , Animales , Conducta Animal , Lesiones Encefálicas/metabolismo , Lesiones Encefálicas/patología , Corteza Cerebral/lesiones , Corteza Cerebral/metabolismo , Corteza Cerebral/patología , Cognición , Regulación hacia Abajo/fisiología , Inmunoglobulina G/farmacología , Masculino , Fibras Nerviosas Mielínicas/metabolismo , Fibras Nerviosas Mielínicas/patología , Regeneración Nerviosa/efectos de los fármacos , Proteínas Nogo , Ratas , Ratas Sprague-DawleyRESUMEN
One strategy for the use of neural stem cells (NSCs) in treating neurological disorders is as transplantable "biological minipumps", in which genetically engineered neural stem cells serve as sources of secreted therapeutic (neuroprotective or tumoricidal) agents. Neural stem cells are highly mobile within the brain and demonstrate a tropism for various types of central nervous system (CNS) pathology, making them promising candidates for targeted gene delivery vehicles. Although neural stem cells have also been proposed as a potential source of replacement neurons and astrocytes to repopulate injured or degenerating neural circuits, the challenges involved in rebuilding damaged brain architecture are substantial and remain an active area of investigation. In contrast, the use of NSCs as biological minipumps does not rely on neuronal differentiation, axonal targeting, or synaptogenesis. This strategy may be a faster route to cell-based therapy of the CNS and is poised to move into human clinical trials. This review considers two types of neurologic disease that may be suitable targets for this alternative approach to NSC therapy: glial brain tumors and traumatic brain injury. We examine some of the key scientific and technical issues that must be addressed for the successful use of NSCs as minipumps.
Asunto(s)
Tratamiento Basado en Trasplante de Células y Tejidos , Enfermedades del Sistema Nervioso Central/terapia , Neuronas/citología , Células Madre/citología , Animales , Lesiones Encefálicas/terapia , Neoplasias del Sistema Nervioso Central/terapia , HumanosRESUMEN
Axonal injury is a hallmark of traumatic brain injury (TBI) and is associated with a poor clinical outcome. Following central nervous system injury, axons regenerate poorly, in part due to the presence of molecules associated with myelin that inhibit axonal outgrowth, including myelin-associated glycoprotein (MAG). The involvement of MAG in neurobehavioral deficits and tissue loss following experimental TBI remains unexplored and was evaluated in the current study using an MAG-specific monoclonal antibody (mAb). Anesthetized rats (n=102) were subjected to either lateral fluid percussion brain injury (n=59) or sham injury (n=43). In surviving animals, beginning at 1 h post-injury, 8.64 microg anti-MAG mAb (n=33 injured, n=21 sham) or control IgG (n=26 injured, n=22 sham) was infused intracerebroventricularly for 72 h. One group of these rats (n=14 sham, n=11 injured) was killed at 72 h post-injury for verification of drug diffusion and MAG immunohistochemistry. All other animals were evaluated up to 8 weeks post-injury using tests for neurologic motor, sensory and cognitive function. Hemispheric tissue loss was also evaluated at 8 weeks post-injury. At 72 h post-injury, increased immunoreactivity for MAG was seen in the ipsilateral cortex, thalamus and hippocampus of brain-injured animals, and anti-MAG mAb was detectable in the hippocampus, fimbria and ventricles. Brain-injured animals receiving anti-MAG mAb showed significantly improved recovery of sensorimotor function at 6 and 8 weeks (P<0.01) post-injury when compared with brain-injured IgG-treated animals. Additionally, at 8 weeks post-injury, the anti-MAG mAb-treated brain-injured animals demonstrated significantly improved cognitive function and reduced hemispheric tissue loss (P<0.05) when compared with their brain-injured controls. These results indicate that MAG may contribute to the pathophysiology of experimental TBI and treatment strategies that target MAG may be suitable for further evaluation.
Asunto(s)
Anticuerpos Monoclonales/farmacología , Lesiones Encefálicas/tratamiento farmacológico , Enfermedades Desmielinizantes/tratamiento farmacológico , Glicoproteína Asociada a Mielina/antagonistas & inhibidores , Recuperación de la Función/efectos de los fármacos , Degeneración Walleriana/tratamiento farmacológico , Animales , Anticuerpos Monoclonales/inmunología , Anticuerpos Monoclonales/uso terapéutico , Axones/efectos de los fármacos , Axones/inmunología , Axones/patología , Encéfalo/efectos de los fármacos , Encéfalo/inmunología , Encéfalo/fisiopatología , Lesiones Encefálicas/inmunología , Lesiones Encefálicas/fisiopatología , Enfermedades Desmielinizantes/inmunología , Enfermedades Desmielinizantes/fisiopatología , Modelos Animales de Enfermedad , Inmunohistoquímica , Masculino , Glicoproteína Asociada a Mielina/inmunología , Regeneración Nerviosa/efectos de los fármacos , Regeneración Nerviosa/inmunología , Ratas , Ratas Sprague-Dawley , Recuperación de la Función/inmunología , Resultado del Tratamiento , Degeneración Walleriana/inmunología , Degeneración Walleriana/fisiopatologíaRESUMEN
The NTera2 (NT2) cell line is a homogeneous population of cells, which, when treated in vitro with retinoic acid, terminally differentiate into postmitotic neuronal NT2N cells. Although NT2N neurons transplanted in the acute (24 h postinjury) period survive for up to 1 month following experimental traumatic brain injury (TBI), nothing is known of their ability to survive for longer periods or of their effects when engrafted during the chronic postinjury period. Adult male Sprague-Dawley rats (n = 348; 360-400 g) were initially anesthetized and subjected to severe lateral fluid-percussion (FP) brain injury or sham injury. At 1 month postinjury, only brain-injured animals showing severe neurobehavioral deficits received cryopreserved NT2N neurons stereotaxically transplanted into three sites in the peri-injured cortex (n = 18). Separate groups of similarly brain-injured rats received human fibroblast cells (n = 13) or cell suspension vehicle (n = 14). Sham-injured animals (no brain injury) served as controls and received NT2N transplants (n = 24). All animals received daily immunosuppression for three months. Behavioral testing was performed at 1, 4, 8, and 12 weeks post-transplantation, after which animals were sacrificed for histological analysis. Nissl staining and anti-human neuronal specific enolase (NSE) immunostaining revealed that NT2N neurons transplanted in the chronic post-injury period survived up to 12 weeks post-transplantation, extended processes into the host cortex and immunolabeled positively for synaptophysin. There were no statistical differences in cognitive or motor function among the transplanted brain-injured groups. Long-term graft survival suggests that NT2N neurons may be a viable source of neural cells for transplantation after TBI and also that these grafts can survive for a prolonged time and extend processes into the host cortex when transplanted in the chronic post-injury period following TBI.
Asunto(s)
Conducta Animal/fisiología , Lesiones Encefálicas/terapia , Supervivencia de Injerto/fisiología , Neuronas/trasplante , Trasplante Heterólogo , Animales , Lesiones Encefálicas/patología , Línea Celular , Humanos , Inmunohistoquímica , Masculino , Actividad Motora/fisiología , Neuronas/metabolismo , Fosfopiruvato Hidratasa/metabolismo , Ratas , Ratas Sprague-Dawley , Recuperación de la Función , TrasplantesRESUMEN
In this report, our findings highlighted the presence of a high level of calcium in the cortex following traumatic brain injury (TBI) in a rat model of fluid percussion-induced brain injury. This calcium increase represents a pitfall in the assessment of Ca2+-independent nitric oxide synthase (NOS) activity supposed to play a role in the secondary brain lesion following TBI. The so-called Ca2+-independent NOS activity measured in the injured cortex 72 h after TBI had the pharmacological profile of a Ca2+-dependent NOS and was therefore inhibited with a supplement of calcium chelator. The remaining activity was very low and iNOS protein was hardly immunodetected on the same sample used for NOS activity assay. The concentration of calcium chelator used in the assay should be revised and adjusted consequently to make sure that the calcium-free condition is achieved for the assay. Otherwise, the findings tend towards an overestimation of Ca2+-independent and underestimation of Ca2+-dependent NOS activities. The revised Ca2+-independent NOS activity assay was then tested, in relation with the amount of iNOS protein, in a model of LPS-induced neuroinflammation. Taken together, precautions should be taken when assessing the Ca2+-independent enzymatic activity in cerebral tissue after a brain insult.
Asunto(s)
Lesiones Encefálicas/enzimología , Calcio/metabolismo , Corteza Cerebral/enzimología , Óxido Nítrico Sintasa/metabolismo , Análisis de Varianza , Animales , Western Blotting/métodos , Lesiones Encefálicas/inducido químicamente , Lesiones Encefálicas/metabolismo , Cerebelo/efectos de los fármacos , Cerebelo/enzimología , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/metabolismo , Quelantes/farmacología , Relación Dosis-Respuesta a Droga , Ácido Edético/farmacología , Encefalitis/inducido químicamente , Encefalitis/enzimología , Regulación de la Expresión Génica/efectos de los fármacos , Concentración 50 Inhibidora , Lipopolisacáridos , Masculino , Óxido Nítrico Sintasa de Tipo II , Percusión/métodos , Neumonía/inducido químicamente , Neumonía/enzimología , Ratas , Ratas Sprague-DawleyRESUMEN
Experimental research during the past decade has greatly increased our understanding of the pathophysiology of traumatic brain injury (TBI) and allowed us to develop neuroprotective pharmacological therapies. Encouraging results of experimental pharmacological interventions, however, have not been translated into successful clinical trials, to date. Traumatic brain injury is now believed to be a progressive degenerative disease characterized by cell loss. The limited capacity for self-repair of the brain suggests that functional recovery following TBI is likely to require cellular transplantation of exogenous cells to replace those lost to trauma. Recent advances in central nervous system transplantation techniques involve technical and experimental refinements and the analysis of the feasibility and efficacy of transplantation of a range of stem cells, progenitor cells and postmitotic cells. Cellular transplantation has begun to be evaluated in several models of experimental TBI, with promising results. The following is a compendium of these new and exciting studies, including a critical discussion of the rationale and caveats associated with cellular transplantation techniques in experimental TBI research. Further refinements in future research are likely to improve results from transplantation-based treatments for TBI.
Asunto(s)
Lesiones Encefálicas/terapia , Degeneración Nerviosa/terapia , Trasplante de Células Madre/tendencias , Células Madre/fisiología , Animales , Lesiones Encefálicas/fisiopatología , Línea Celular/fisiología , Supervivencia de Injerto/fisiología , Humanos , Degeneración Nerviosa/etiología , Degeneración Nerviosa/fisiopatología , Regeneración Nerviosa/fisiología , Trasplante de Células Madre/métodosRESUMEN
During the past decade, there has been accumulating evidence of the involvement of passive and active cell death mechanisms in both the clinical setting and in experimental models of traumatic brain injury (TBI). Traditionally, research for a treatment of TBI consists of strategies to prevent cell death using acute pharmacological therapy. However, to date, encouraging experimental work has not been translated into successful clinical trials. The development of cell replacement therapies may offer an alternative or a complementary strategy for the treatment of TBI. Recent experimental studies have identified a variety of candidate cell lines for transplantation into the injured CNS. Additionally, the characterization of the neurogenic potential of specific regions of the adult mammalian brain and the elucidation of the molecular controls underlying regeneration may allow for the development of neuronal replacement therapies that do not require transplantation of exogenous cells. These novel strategies may represent a new opportunity of great interest for delayed intervention in patients with TBI.
Asunto(s)
Lesiones Encefálicas/fisiopatología , Lesiones Encefálicas/terapia , Muerte Celular , Regeneración Nerviosa , Animales , Modelos Animales de Enfermedad , Humanos , Etiquetado Corte-Fin in Situ/métodos , Coloración y Etiquetado/métodos , Trasplante/métodosRESUMEN
Human Ntera-2 (NT2) cells can be differentiated in vitro into well-characterized populations of NT2N neurons that engraft and mature when transplanted into the adult CNS of rodents and humans. They have shown promise as treatments for neurologic disease, trauma, and ischemic stroke. Although these features suggest that NT2N neurons would be an excellent platform for ex vivo gene therapy in the CNS, stable gene expression has been surprisingly difficult to achieve in these cells. In this report we demonstrate stable, efficient, and nontoxic gene transfer into undifferentiated NT2 cells using a pseudotyped lentiviral vector encoding the human elongation factor 1-alpha promoter and the reporter gene eGFP. Expression of eGFP was maintained when the NT2 cells were differentiated into NT2N neurons after treatment with retinoic acid. When transplanted into the striatum of adult nude mice, transduced NT2N neurons survived, engrafted, and continued to express the reporter gene for long-term time points in vivo. Furthermore, transplantation of NT2N neurons genetically modified to express nerve growth factor significantly attenuated cognitive dysfunction following traumatic brain injury in mice. These results demonstrate that defined populations of genetically modified human NT2N neurons are a practical and effective platform for stable ex vivo gene delivery into the CNS.
Asunto(s)
Lesiones Encefálicas/terapia , Técnicas de Transferencia de Gen/tendencias , Terapia Genética/métodos , Neuronas/metabolismo , Neuronas/trasplante , Trasplante de Células Madre/métodos , Células Madre/metabolismo , Animales , Diferenciación Celular/genética , Femenino , Regulación de la Expresión Génica/genética , Terapia Genética/tendencias , Vectores Genéticos/uso terapéutico , Supervivencia de Injerto/efectos de los fármacos , Supervivencia de Injerto/genética , Proteínas Fluorescentes Verdes , Humanos , Lentivirus/genética , Proteínas Luminiscentes , Ratones , Ratones Desnudos , Factor de Crecimiento Nervioso/genética , Factor de Crecimiento Nervioso/uso terapéutico , Células PC12 , Factor 1 de Elongación Peptídica/genética , Factor 1 de Elongación Peptídica/uso terapéutico , Ratas , Recuperación de la Función/efectos de los fármacos , Recuperación de la Función/genética , Trasplante de Células Madre/tendencias , Resultado del Tratamiento , Tretinoina/farmacologíaRESUMEN
The adult central nervous system (CNS) appears to initiate a transient increase in plasticity following injury, including increases in growth-related proteins and generation of new cells. Recent evidence is reviewed that the injured adult CNS exhibits events and patterns of gene expression that are also observed during development and during regeneration following damage to the mature peripheral nervous system (PNS). The growth of neurons during development or regeneration is correlated, in part, with a coordinated expression of growth-related proteins, such as growth-associated-protein-43 (GAP-43), microtubule-associated-protein-1B (MAP1B), and polysialylated-neural-cell-adhesion-molecule (PSA-NCAM). For each of these proteins, evidence is discussed regarding its specific role in neuronal development, signals that modify its expression, and reappearance following injury. The rate of adult hippocampal neurogenesis is also affected by numerous endogenous and exogenous factors including injury. The continuing study of developmental neurobiology will likely provide further gene and protein targets for increasing plasticity and regeneration in the mature adult CNS.